Liver Cancer
Larotrectinib / Vitrakvi (Everest)
Price range: £269.00 through £554.00Larotrectinib (Brand name: Vitrakvi) manufactured by Everest Pharma is a targeted therapy used for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring NTRK gene fusions, regardless of where the cancer originated in the body.
Larotrectinib became the first FDA-approved tumor-agnostic targeted therapy based solely on the presence of a specific genetic mutation rather than cancer type or tumor location.
Clinical studies demonstrated efficacy across 17 different adult and pediatric tumor types, highlighting its broad-spectrum anticancer activity in patients with NTRK fusion-positive cancers.
Cabozantinib (Everest)
Original price was: £299.00.£245.00Current price is: £245.00.Cabozantinib manufactured by Everest Pharma is a multi-target broad-spectrum anticancer therapy that has demonstrated promising clinical efficacy across a wide range of solid tumors.
Cabozantinib has shown beneficial treatment effects in:
- Renal cell carcinoma (kidney cancer)
- Thyroid cancer
- Liver cancer
- Soft tissue sarcoma
- Non-small cell lung cancer (NSCLC)
- Prostate cancer
- Breast cancer
- Ovarian cancer
- Colorectal cancer
and several other advanced malignancies.
Cabozantinib is particularly recognized for its strong effectiveness in controlling bone metastases, helping reduce tumor progression and complications associated with metastatic bone disease.
Due to its broad antitumor activity across multiple cancer types, Cabozantinib is often referred to as a “multi-purpose” or “broad-spectrum” targeted therapy among tyrosine kinase inhibitors (TKIs).